Viropharma Inc (VPHM), Actavis Inc (ACT), Akorn, Inc. (AKRX): Can This Experimental Drug Be Brought Back From the Dead?

ViroPharma is certainly still dealing with the stigma of losing its previous workhorse in Vancocin, but its future is again looking bright. I figured there was an outside chance that the 2009 data from maribavir was bound to induce ViroPharma to dig deeper, especially with CMV disease having no cure, and it appears my speculation was correct. I would keep a very close eye on ViroPharma moving forward as it appears to have the right tools and the budding pipeline to really surprise Wall Street and investors.

The article Can This Experimental Drug Be Brought Back From the Dead? originally appeared on Fool.com and is written by Sean Williams.

Fool contributor Sean Williams has no material interest in any companies mentioned in this article. You can follow him on CAPS under the screen name TMFUltraLong, track every pick he makes under the screen name TrackUltraLong, and check him out on Twitter, where he goes by the handle @TMFUltraLong.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.